13
Resistance in Clinical
Isolates Adverse Events Evidence Supporting Efficacy
N/A Caution for use
in patients with
congestive heart
failure
Two Phase III RCTs comparisons
to metronidazole, vancomycin, or
fidaxomicin; U.S. FDA-Approved.
One clinical isolate with
increased MIC
Minimally absorbed Two Phase III RCT comparisons to
vancomcyin; U.S. FDA-Approved
Not reported Minimally absorbed Multiple RCTs; U.S. FDA-Approved
Increased MIC reported
in some studies; Hetero-
resistance also reported
Neuropathy, Nausea Multiple RCTs
Not reported GI symptoms Small RCT comparison to
vancomycin and a modest sized RCT
comparison to metronidazole
Reported to develop in
vivo resistance
GI symptoms Modest-sized RCT comparison to
metronidazole and a small RCT
comparison to vancomycin
Potential for
development of high-
level resistance
Minimally absorbed One small RCT comparison to
vancomycin for primary treatment
Case series and one RCT pilot
study show promise for use as a
post-vancomycin 'chaser' strateg y in
management of recurrent CDI
Not reported GI symptoms Case reports and small case series
Increasing resistance
noted
Minimally
absorbed, poor taste
Two small RCT comparisons to
vancomycin
